Dalzanemdor

Dalzanemdor
Clinical data
Other namesSAGE-718
Routes of
administration		Oral
Drug classNMDA receptor positive allosteric modulator; Neurosteroid
ATC code
  • None
Legal status
Legal status
  • Investigational
Identifiers
  • (3S,8R,9S,10R,13R,14S,17R)-3,13-Dimethyl-17-[(2R,5S)-6,6,6-trifluoro-5-hydroxy-5-methylhexan-2-yl]-2,4,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
CAS Number
PubChem CID
ChemSpider
KEGG
ChEMBL
Chemical and physical data
FormulaC26H41F3O2
Molar mass442.607 g·mol−1
3D model (JSmol)
  • C[C@H](CC[C@@](C)(C(F)(F)F)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@H]3CC[C@](C4)(C)O)C
  • InChI=1S/C26H41F3O2/c1-16(9-14-25(4,31)26(27,28)29)21-7-8-22-20-6-5-17-15-23(2,30)12-10-18(17)19(20)11-13-24(21,22)3/h5,16,18-22,30-31H,6-15H2,1-4H3/t16-,18+,19-,20-,21-,22+,23+,24-,25+/m1/s1
  • Key:RTBRKGVJBGKMFF-YMEFNWBESA-N

Dalzanemdor (INNTooltip International Nonproprietary Name; development code SAGE-718) is experimental drug that was previously investigated for the treatment of neurological disorders and cognitive impairment. It acts as a positive allosteric modulator of the NMDA receptor, whose activity is essential for learning, memory, and cognition. Dalzanemdor is an analogue of the neurosteroid 24S-hydroxycholesterol.

As of 2022, dalzanemdor is in Phase II clinical trials for Alzheimer's disease, Parkinson's disease, and Huntington's disease. As of 2024, Sage Therapeutics had discontinued development of dalzanemdor following negative clinical trial results.

References

  1. 1 2 3 "Sage Therapeutics". AdisInsight. 1 August 2025. Retrieved 5 June 2026.
  2. ↑ "Investigational SAGE-718 Granted Nonproprietary Name of Dalzanemdor". Sage Therapeutics. December 5, 2023.
  3. ↑ Hill MD, Blanco MJ, Salituro FG, Bai Z, Beckley JT, Ackley MA, et al. (July 2022). "SAGE-718: A First-in-Class N-Methyl-d-Aspartate Receptor Positive Allosteric Modulator for the Potential Treatment of Cognitive Impairment". Journal of Medicinal Chemistry. 65 (13): 9063–9075. doi:10.1021/acs.jmedchem.2c00313. PMID 35785990. S2CID 250250073.
  4. 1 2 3 "SAGE-718". ALZFORUM.
  5. ↑ Shapiro L (5 April 2022). "#AAN2022 – SAGE-718 May Help With Cognitive Function in Alzheimer's". BioNews, Inc.
  6. ↑ "SAGE-718 in Patients With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease: Results From the Phase 2 LUMINARY Study" (PDF). American Academy of Neurology (AAN) 74th Annual Meeting Abstract.
  7. ↑ Castañeda R (16 November 2021). "Regulatory roundup: Sage Alzheimer's asset likely to progress after Phase IIa completion". Clinical Trials Arena. Archived from the original on 28 May 2022. Retrieved 13 July 2022.
  8. ↑ "Sage Therapeutics Provides Important Update On The Clinical Development Program For Sage's Investigational Drug, SAGE-718". Huntington's Disease Society of America. 22 February 2022.
  9. ↑ Wexler M (21 September 2021). "SAGE-718 on FDA Fast Track as Potential Huntington's Disease Therapy". BioNews, Inc.
  10. ↑ "Huntington Agent SAGE-718 to be Discontinued Following Disappointing Phase 2 DIMENSION Trial Results". Neurology Live. 20 November 2024.